logo
logo

Leyden Labs Raises $200M In 2021 For A New Approach To Combat Viruses

Jan 25, 2022•over 3 years ago

Amount Raised

$200 Million

Description

Leyden Laboratories B.V., (the "Company" or "Leyden Labs") today announced closing a $140M Series B financing, bringing its total capital raised to approximately $200M in 2021. Series A investors Casdin Capital and GV (formerly Google Ventures) led the round that included incoming investors SoftBank Vision Fund 2, Invus, and Bluebird Ventures, and existing Series A investors F-Prime Capital and Byers Capital/Brook Byers. This international syndicate will support Leyden Labs’ mission to free people from the burden of respiratory viruses. The Board will expand to include Eli Casdin of Casdin Capital as a new member

Company Information

Company

Leyden Labs

About

The platform will also support development of novel broad-protection nasal sprays for coronavirus family and other respiratory diseases. “This fundraising underscores our investors’ belief that Leyden Labs’ platform can generate cornerstone products to combat respiratory diseases. Leyden Labs has a pipeline of mucosal protection products, including PanFlu which uses CR9114, the only human monoclonal influenza antibody that protects against influenza A and B, in-licensed from Janssen Pharmaceuticals.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech